At this time, there is no approved or
authorized Covid-19 protection for babies under 6 months old, leaving
them vulnerable at daycare, at family functions, and even
at home as older siblings head back to school.
The vaccine being evaluated in the BabyCOVE Study is
Moderna’s “bivalent” (addressing 2 viral strains at the same
time) investigational COVID-19 vaccine. It is being evaluated at
2 dosing levels to find out which is the safest and most effective
dose for infants.
